Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CD74 | P04233 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296890 | 0.87 | TSHR (0.80) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL18805676 | 0.86 | KMT2A (0.76) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL17312313 | 0.84 | TSHR (0.65) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL2757836 | 0.83 | MIF (1.00) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL29566285 | 0.83 | MIF (1.00) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL16296741 | 0.82 | TSHR (0.63) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL18402541 | 0.81 | TSHR (0.65) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL18402538 | 0.81 | TSHR (0.62) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL18805679 | 0.81 | KMT2A (1.00) | MIFKMT2AMEN1POLBCD74 | |
| SCHEMBL10874258 | 0.81 | MIF (1.00) | MIFKMT2AMEN1POLBCD74 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584717-B2 | MIF modulators | YALE UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220143128-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | BCELL SOLUTIONS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20200377457-A1 | MIF MODULATORS | UNIV YALE (US) | 2020-12-03 | — | — | US | disclosed |
| US-20190270706-A1 | MIF MODULATORS | UNIV YALE (US) | 2019-09-05 | — | — | US | disclosed |
| US-10202343-B2 | MIF modulators | YALE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180162813-A1 | MIF MODULATORS | YALE UNIVERSITY | 2018-06-14 | — | — | US | disclosed |
| US-20180162813-A1 | MIF MODULATORS | YALE UNIVERSITY | 2018-06-14 | — | — | US | disclosed |
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9540322-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540322-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-01-10 | — | — | US | disclosed |
| US-20120004261-A1 | MIF MODULATORS | YALE UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004261-A1 | MIF MODULATORS | YALE UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100267714-A1 | MIF MODULATORS | YALE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| US-20100267714-A1 | MIF MODULATORS | YALE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584717-B2 | MIF modulators | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
| US-20200377457-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
| US-20180162813-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
| US-20220143128-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CD74, MIF, MICA | MIF 2/4885KMT2A 2667/4885MEN1 3592/4885 |
| US-20120004261-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
| US-20100267714-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
| US-10202343-B2 | MIF modulators | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
| US-20190270706-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | MIF 1/4885KMT2A 2950/4885MEN1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.